[ad_1]
The NICE Final Guidance Project has recommended interim funding for fulvestrant by Eli Lilly's Verzenios (abemaciclib) with the NHS, offering some bad cancer patients an option to delay chemotherapy after endocrine treatment.
About 4,800 women likely to benefit from this treatment had previously received endocrine therapy for hormone-receptor-positive bad cancer, HER2-negative, which had spread to other parts of the body. This will be an option where exemestane plus everolimus would be the most appropriate alternative treatment.
The body said that Verzenios will be available as soon as the final draft guidelines have been published and that it will be reimbursed by the Cancer Fund, until data confirms the report. cost / effectiveness are available.
Verzenios is the first CDK4 / 6 inhibitor to be badociated with fulvestrant as a second-line treatment option for women whose disease has progressed while taking an aromatase inhibitor.
The rival inhibitors of CDK4 / 6, Ibrance and Kisqali from Pfizer and Novartis, respectively, were available only in combination with aromatase inhibitors.
Evidence from clinical trials suggests that, compared to fulvestrant alone, Verzenios badociated with fulvestrant increases the time to disease progression.
NICE has stated that it lacks evidence on the benefits in terms of survival and its cost-effectiveness, which means that its use within the CDF has been recommended while more data is being collected.
These directions will be revisited when the final badysis of the MONARCH 2 Phase 3 study is available, which should take place in February 2020.
A managed access agreement between Eli Lilly, NICE and NHS England provides for a data collection period until December 2021.
Verzenios is given as a tablet twice a day and works by inhibiting the proteins contained in the cancer cells that allow it to divide and grow.
A pack of 56 150 mg tablets normally costs £ 2 950, but Lilly has provided a confidential discount under the managed access agreement.
Meindert Boysen, director of the NICE Center for Health Technology Assessment, said: "Patients have explained to the committee that a treatment likely to delay or avoid the use of chemotherapy is important because chemotherapy can potentially significantly reduce the quality of life.
"They also stressed how important it is for people to stay healthier longer without the disease evolving.
"Today's recommendation is another example of NICE's effective collaboration with the NHS England to give people faster access to promising cancer treatments through the Cancer Fund."
Source link
